Physician profile
John Jin Kim
NPI 1508050220
$5,479.12
in general payments reported to CMS, 2019-2025
22 companies · $128 in 2025
The $128 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,273 · 2020: $140 · 2021: $396 · 2022: $129 · 2023: $320 · 2024: $93.42 · 2025: $128.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $541.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,952.83 | 2019-2021 | |
| Alcon Vision LLC | $380.36 | 2019-2025 | Clareon, Argos, Rocklatan |
| Bausch & Lomb Americas INC. | $248.86 | 2023-2024 | Envista Mx60 Iol, Amvisc, Sofport Ao |
| Johnson & Johnson Surgical Vision, INC. | $140.10 | 2019 | |
| Aerie Pharmaceuticals, INC. | $135.61 | 2019-2021 | |
| Glaukos Corporation | $109.94 | 2019 | |
| Sun Pharmaceutical Industries INC. | $65.63 | 2019 | |
| Dompe US, INC. | $62.36 | 2021-2025 | Oxervate |
| Horizon Therapeutics Plc | $58.00 | 2022-2023 | Tepezza |
| Abbvie INC. | $50.26 | 2023-2025 | |
| Kala Pharmaceuticals, INC. | $48.55 | 2021-2022 | |
| Shire North American Group INC | $45.93 | 2019 | |
| Ani Pharmaceuticals, INC. | $23.32 | 2025 | Purified Cortrophin Gel |
| Sight Sciences, INC. | $20.85 | 2021 | |
| Rxsight INC | $19.65 | 2023 | Rxsight Light Delivery Device (Ldd), Rxsight Injector Handpiece, Rxsight Injector Cartridge |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Rayner Intraocular Lenses Limited | $19.58 | 2022 | |
| Mallinckrodt Hospital Products INC. | $19.19 | 2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $17.58 | 2019 | |
| Eyevance Pharmaceuticals LLC | $16.61 | 2021 | |
| Coherus Oncology, INC. | $15.95 | 2023 | |
| Amgen INC. | $14.96 | 2025 | Tepezza |
| Biotissue Holdings INC. | $13.00 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.